In-silico design of novel 2-((4-chloro-6-methoxy-1H-indol-3-yl) thio)-N-(2-ethoxyphenyl)acetamide derivatives as potential inhibitors of influenza neuraminidase protein receptor

Abstract

Influenza virus transmission is largely mediated by its mutation and genome reassortment from distinct strains resulting in drug-resistances and pandemics. This necessitates the need for the discovery of more potential influenza inhibitors to prevent future epidemics. An in-silico approach was utilized here to design six new (21a-f) potential inhibitors of influenza neuraminidase (NA) using a hit compound 21 with good binding affinity, predicted activity, and pharmacokinetic properties in our previous work. The modeled activities (pEC₅₀) of the newly designed compounds (ranging between 8.188 and 7.600) were better than that of the hit compound 21 with predicted activity (pEC₅₀) of 6.0101 and zanamivir (pEC₅₀ of 5.6755) as the standard reference control used. The MolDock scores (ranging between -189.67 and -142.47 kcal/mol) of these newly designed compounds in the NA binding cavity were also better than the hit template 21 with a MolDock score of -125.33 kcal/mol and zanamivir standard drug (-136.36 kcal/mol). In addition, the conformational stability of the best-designed compound 21a in the NA binding cavity was further studied through the MD simulation of 100 ns. Moreover, the drug-likeness and ADMET predictions of these designed compounds showed their good oral bioavailability and pharmacokinetic profiling respectively. More so, the DFT calculations also revealed the relevance of these designed compounds in view of their smaller band energy gaps from the frontier molecular orbital calculations. This study could serve as a reliable in-silico perspective for the search and discovery of potential anti-influenza agents.

Keywords

Neuraminidase / Active cavity / Hydrogen bonds / Reactivity / Bioavailability

References

[1] Abdelgawad MA, Oh JM, Parambi DGT, et al. Development of bromo- and fluorobased α β-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson’s disease. J Mol Struct. 2022;1266:133545.

[2] Abdizadeh R, Hadizadeh F, Abdizadeh T. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. J Biomol Struct Dyn. 2022:1–31.

[3] Abdullahi M, Adeniji SE, Arthur DE, Musa S. Quantitative structure-activity relationship (QSAR) modelling study of some novel carboxamide series as new anti-tubercular agents. Bull Natl Res Cent. 2020a;44(1):1–13.

[4] Abdullahi M, Uzairu A, Shallangwa GA, Arthur DE, Umar BA, Ibrahim MT. Virtual molecular docking study of some novel carboxamide series as new anti-tubercular agents. Eur J Chem. 2020b;11(1):30–36.

[5] Abdullahi M, Uzairu A, Shallangwa GA, Mamza PA, Ibrahim MT. 2D-QSAR, 3D-QSAR, molecular docking and ADMET prediction studies of some novel 2-((1H-indol-3-yl)thio)-N-phenyl-acetamide derivatives as anti-influenza A virus. Egyptian J Basic Appl Sci. 2022;9(1):510–532.

[6] Abdullahi M, Uzairu A, Shallangwa GA, et al. Molecular modelling studies of substituted indole derivatives as novel influenza a virus inhibitors. J Biomol Struct Dyn. 2023:1–20.

[7] Abisha W, Dhas DA, Balachandran S, Joe IH. Molecular Structure, Spectroscopic Elucidation (FT-IR, FT-Raman, UV-Visible and NMR) with NBO, ELF, LOL, RDG, Fukui, Drug Likeness and Molecular Docking Analysis on Dimethomorph. Polycyclic Aromatic Compounds; 2022:1–44.

[8] Acar Çevik U, Celik I, Işık A, et al. Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1, 3, 4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors. J Biomol Struct Dyn. 2022:1–15.

[9] Adekoya OC, Adekoya GJ, Sadiku ER, Hamam Y, Ray SS. Application of DFT calculations in designing polymer-based drug delivery systems: an overview. Pharmaceutics. 2022;14(9):1972.

[10] Adlhoch C, Pebody R. What to expect for the influenza season 2020/21 with the ongoing COVID-19 pandemic in the World Health Organization European Region. Euro Surveill. 2020;25(42):2001816.

[11] Ahmad I, Pawara R, Patel H. In silico toxicity investigation of Methaqualone’s conjunctival, retinal, and gastrointestinal hemorrhage by molecular modelling approach. Mol Simulat. 2022:1–11.

[12] Alghamdi SK, Abbas F, Hussein RK, Alhamzani AG, El-Shamy NT. Spectroscopic characterization (IR, UV-vis), and HOMO-LUMO, MEP, NLO, NBO analysis and the antifungal activity for 4-bromo-N-(2-nitrophenyl) benzamide; using DFT modeling and in silico molecular docking. J Mol Struct. 2023;1271:134001.

[13] Arthur DE, Samuel AN, Ejeh S, Adeniji SE, Adedirin O, Abdullahi M. Computational study of some cancer drugs as potent inhibitors of GSK3β. Scientific African. 2020;10: e00612.

[14] Aziz M, Ejaz SA, Tamam N, et al. Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach. Sci Rep. 2022;12(1):1–17.

[15] Baammi S, Daoud R, El Allali A. In silico protein engineering shows that novel mutations affecting NAD+ binding sites may improve phosphite dehydrogenase stability and activity. Sci Rep. 2023;13(1):1878.

[16] Babalola S, Igie N, Odeyemi I. Structure-based Discovery of Multitarget Directed Anti-inflammatory P-Nitrophenyl Hydrazones; Molecular Docking, Drug-Likeness, In-Silico Pharmacokinetics, and Toxicity Studies. 2022.

[17] Boulaamane Y, Ahmad I, Patel H, Das N, Britel MR, Maurady A. Structural exploration of selected C6 and C7-substituted coumarin isomers as selective MAO-B inhibitors. J Biomol Struct Dyn. 2022:1–15.

[18] Chaudhari B, Patel H, Thakar S, Ahmad I, Bansode D. Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach. Silico Pharmacol. 2022;10(1):1–14.

[19] Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2022:1–16.

[20] Chuang Y-C, Lin K-P, Wang L-A, Yeh T-K, Liu P-Y. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist. 2023:661–675.

[21] Desai NC, Joshi SB, Khasiya AG, et al. Pyrazolo-imidazolidinones: synthesis, antimicrobial assessment and molecular modelling studies by molecular mechanic and quantum mechanic approach. J Mol Struct. 2022;1270:134000.

[22] ElMchichi L, Belhassan A, Lakhlifi T, Bouachrine M. 3D-QSAR study of the chalcone derivatives as anticancer agents. J Chem. 2020, 2020.

[23] Eno EA, Louis H, Ekoja P, et al. Experimental and computational modeling of the biological activity of benzaldehyde sulphur trioxide as a potential drug for the treatment of Alzheimer disease. J Indian Chem Soc. 2022;99(7):100532.

[24] Esposito S, Nauta J, Lapini G, Montomoli E, van de Witte S. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6–35 months: a global, multiseasonal, controlled, randomized Phase III study. Vaccine. 2022;40(18): 2626–2634.

[25] Farhan MM, Guma MA, Rabeea MA, Ahmad I, Patel H. Synthesizes, characterization, molecular docking and in vitro bioactivity study of new compounds containing triple beta lactam rings. J Mol Struct. 2022;1269:133781.

[26] Fazl i S, Ahmed A, Ullah H, Ullah Z, Tariq M, Ayub K. External stimulus controlled recombination of hydrogen in photochromic dithienylethene frustrated lewis pairs. Int J Hydrogen Energy. 2019;44(59):31141–31152.

[27] Garg A, Dewangan HK. Recent advances in drug design and delivery across biological barriers using computational models. Lett Drug Des Discov. 2022;19(10):865–876.

[28] Gubareva L, Mohan T. Antivirals targeting the neuraminidase. Cold Spring Harbor Perspect Med. 2022;12(1):a038455.

[29] Huang W-j, Cheng Y-h, Tan M-j, et al. Epidemiological and virological surveillance of influenza viruses in China during 2020–2021. Infectious Diseas Povert. 2022;11(1): 1–15.

[30] Hussein HA, Fadhil GF. Theoretical Investigation of para Amino-Dichloro Chalcone Isomers. Part II: a DFT Structure–Stability Study of the FMO and NLO Properties. ACS Omega. 2023.

[31] Ibrahim MT, Uzairu A, Uba S, Shallangwa GA. Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach. Future J Pharmaceut Sci. 2021;7(1):140.

[32] Inaida S, Matsuno S, Okumura J. Longitudinal surveillance of influenza in Japan, 2006–2016. Sci Rep. 2022;12(1):1–9.

[33] Janani S, Rajagopal H, Muthu S, Aayisha S, Raja M. Molecular structure, spectroscopic (FT-IR, FT-Raman, NMR), HOMO-LUMO, chemical reactivity, AIM, ELF, LOL and Molecular docking studies on 1-Benzyl-4-(N-Boc-amino) piperidine. J Mol Struct. 2021;1230:129657.

[34] Jha V, Dhamapurkar V, Thakur K, et al. Molecular mechanism of interaction between influenza virus and host cells: an attempt to understand signaling and cellular pathways. Prev Med. 2022;1(1):1002.

[35] Kar S, Roy K, Leszczynski J. In silico tools and software to predict ADMET of new drug candidates. In: In Silico Methods for Predicting Drug Toxicity. Springer; 2022: 85–115.

[36] Karami TK, Hailu S, Feng S, Graham R, Gukasyan HJ. Eyes on Lipinski’s rule of five: a new “rule of Thumb” for physicochemical design space of ophthalmic drugs. J Ocul Pharmacol Therapeut. 2022;38(1):43–55.

[37] Kausar N, Murtaza S, Khalid M, et al. Experimental and quantum chemical approaches for hydrazide-based crystalline organic chromophores: synthesis, SC-XRD, spectroscopic and nonlinear optical properties. J Mol Struct. 2022:134208.

[38] Khalid M, Shafiq I, Mahmood K, et al. Effect of different end-capped donor moieties on non-fullerenes based non-covalently fused-ring derivatives for achieving high-performance NLO properties. Sci Rep. 2023;13(1):1395.

[39] Komadina N, Sullivan SG, Leder K, McVernon J. Likelihood of prior exposure to circulating influenza viruses resulting in cross-protection by CD8+ T cells against emergent H3N2v swine viruses infecting humans. J Med Virol. 2022;94(2):567–574.

[40] Kraithong S, Teerapattarakan N, Balasubramanian B, Issara U. Bioactive compounds in tea: effect of imbalanced intake on digestive enzymes activity, cytochrome inhibition and drug interaction. South Afr J Bot. 2022;150:58–68.

[41] Kumar B, Chawla PA, Chawla V. Computer aided drug design. In: Computer Aided Pharmaceutics and Drug Delivery. Springer; 2022a:505–541.

[42] Kumar R, Mittal A, Kulkarni MP. Quality by design in pharmaceutical development. In: Computer Aided Pharmaceutics and Drug Delivery. Springer; 2022b:99–127.

[43] Laurie KL, Rockman S. Which influenza viruses will emerge following the SARS-CoV-2 pandemic? Influenza Respirat Viruse. 2021;15(5):573–576.

[44] Li H, Sheng Y, Li W, Yuan L. Recent advances in molecular fluorescent probes for CYP450 sensing and imaging. Chemosensors. 2022;10(8):304.

[45] Libera K, Konieczny K, Grabska J, Szopka W, Augustyniak A, Pomorska-Mól M. Selected livestock-associated zoonoses as a growing challenge for public health. Infect Dis Rep. 2022;14(1):63–81.

[46] Ma W. Orthomyxoviridae. Vet Microbiol. 2022:573–588.

[47] Mahapatra MK, Karuppasamy M. Fundamental considerations in drug design. In: Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. Elsevier; 2022:17–55.

[48] Menon D, Ranganathan R. A generative approach to materials discovery, design, and optimization. ACS Omega. 2022;7(30):25958–25973.

[49] Mihalovits LM, Ferenczy GG, Keserű GM. The role of quantum chemistry in covalent inhibitor design. Int J Quant Chem. 2022;122(8):e26768.

[50] Neumann G, Kawaoka Y. Which virus will cause the next pandemic? Viruses. 2023; 15(1):199.

[51] Osmaniye D, Karaca Ş, Kurban B, et al. Design, synthesis, molecular docking and molecular dynamics studies of novel triazolothiadiazine derivatives containing furan or thiophene rings as anticancer agents. Bioorg Chem. 2022;122:105709.

[52] Paul RK, Ahmad I, Patel H, Kumar V, Raza K. Phytochemicals from amberboa ramosa as potential DPP-IV inhibitors for the management of type-II diabetes mellitus: inferences from in-silico investigations. J Mol Struct. 2022:134045.

[53] Poleboyina PK, Rampogu S, Doneti R, et al. Screening and identification of potential iNOS inhibitors to curtail cervical cancer progression: an in silico drug repurposing approach. Appl Biochem Biotechnol. 2022;194(1):570–586.

[54] Prosperi S, Chiarelli F. COVID-19 and diabetes in children. Annal Pediatric Endocrinol Metabol. 2022;27(3):157–168.

[55] Radwan HA, Ahmad I, Othman IM, et al. Design, synthesis, in vitro anticancer and antimicrobial evaluation, SAR analysis, molecular docking and dynamic simulation of new pyrazoles, triazoles and pyridazines based isoxazole. J Mol Struct. 2022: 133312.

[56] Ramos-Martínez IE, Ramos-Martínez E, Segura-Velázquez RÁ, et al. Heparan sulfate and sialic acid in viral attachment: two sides of the same coin? Int J Mol Sci. 2022; 23(17):9842.

[57] Razanajatovo NH, Randriambolamanantsoa TH, Rabarison JH, et al. Epidemiological patterns of seasonal respiratory viruses during the COVID-19 pandemic in Madagascar, march 2020–may 2022. Viruses. 2023;15(1):12.

[58] Shah A, Jain M. Limitations and future challenges of computer-aided drug design methods. In: Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. Elsevier; 2022:283–297.

[59] Szczesniak I, Baliga-Gil A, Jarmolowicz A, Soszynska-Jozwiak M, Kierzek E. Structural and functional RNA motifs of SARS-CoV-2 and influenza A virus as a target of viral inhibitors. Int J Mol Sci. 2023;24(2):1232.

[60] Taghour MS, Elkady H, Eldehna WM, et al. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway. PLoS One. 2022;17(9):e0272362.

[61] Tople MS, Patel NB, Patel PP, Purohit AC, Ahmad I, Patel H. An in silico-in vitro antimalarial and antimicrobial investigation of newer 7-Chloroquinoline based Schiff-bases. J Mol Struct. 2022:134016.

[62] Ullah H. Inter-molecular interaction in Polypyrrole/TiO2: a DFT study. J Alloys Compd. 2017;692:140–148.

[63] Ullah H, Tahir AA, Mallick TK. Polypyrrole/TiO2 composites for the application of photocatalysis. Sensor Actuator B Chem. 2017;241:1161–1169.

[64] Umar BA, Uzairu A, Shallangwa GA, Sani U. QSAR modeling for the prediction of pGI50 activity of compounds on LOX IMVI cell line and ligand-based design of potent compounds using in silico virtual screening. Network Model Analys Health Inform Bioinform. 2019;8(1):1–10.

[65] Uniyal A, Mahapatra MK, Tiwari V, Sandhir R, Kumar R. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. J Biomol Struct Dyn. 2022;40(8):3609–3625.

[66] Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol. 2017;27(14):R713–R715.

[67] Wilasang C, Suttirat P, Chadsuthi S, Wiratsudakul A, Modchang C. Competitive evolution of H1N1 and H3N2 influenza viruses in the United States: a mathematical modeling study. J Theor Biol. 2022:111292.

[68] Xu M, Li X, Zheng H, Chen J, Ye X, Liu T. Anti-influenza virus study of composite material with MIL-101 (Fe)-Adsorbed favipiravir. Molecules. 2022;27(7):2288.

[69] Yu D, Wang L, Wang Y. Recent advances in application of computer-aided drug design in anti-influenza A virus drug discovery. Int J Mol Sci. 2022;23(9):4738.

[70] Zahra A, Thorne M, Psevdos G. Detection of non–SARS-CoV-2 respiratory viruses in US veterans during the second year of the COVID-19 pandemic. Infect Dis Clin Pract. 2023;31(2):1–3.

[71] Zhang R, Peng Z, Meng Y, et al. Temperature and Influenza Transmission: Risk Assessment and Attributable Burden Estimation Among 30 Cities in China. Environmental Research; 2022:114343.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.